These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 1776388

  • 21. Effects of L-deprenyl on parkinsonian bradyphrenia.
    Eatough VM, Kempster PA, Frankel JP, Curry SH, Rogers D, Lees AJ, Stern GM.
    Adv Neurol; 1990; 53():441-3. PubMed ID: 2122651
    [No Abstract] [Full Text] [Related]

  • 22. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
    Heinonen EH, Myllylä V.
    Drug Saf; 1998 Jul; 19(1):11-22. PubMed ID: 9673855
    [Abstract] [Full Text] [Related]

  • 23. Effect of selegiline (deprenyl) on the progression of disability in early Parkinson's disease. Parkinson Study Group.
    Shults CW.
    Acta Neurol Scand Suppl; 1993 Jul; 146():36-42. PubMed ID: 8333252
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.
    Hanagasi HA, Gurvit H, Unsalan P, Horozoglu H, Tuncer N, Feyzioglu A, Gunal DI, Yener GG, Cakmur R, Sahin HA, Emre M.
    Mov Disord; 2011 Aug 15; 26(10):1851-8. PubMed ID: 21500280
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.
    Olanow CW, Myllylä VV, Sotaniemi KA, Larsen JP, Pålhagen S, Przuntek H, Heinonen EH, Kilkku O, Lammintausta R, Mäki-Ikola O, Rinne UK.
    Neurology; 1998 Sep 15; 51(3):825-30. PubMed ID: 9748034
    [Abstract] [Full Text] [Related]

  • 29. Optoelectronic movement analysis in Parkinson's disease: effect of selegiline on the disability in de novo parkinsonian patients--a pilot study.
    Johnels B, Ingvarsson PE, Matousek M, Steg G, Heinonen EH.
    Acta Neurol Scand Suppl; 1991 Sep 15; 136():40-3. PubMed ID: 1801536
    [Abstract] [Full Text] [Related]

  • 30. Selegiline in Parkinson's disease.
    Teräväinen H.
    Acta Neurol Scand; 1990 Apr 15; 81(4):333-6. PubMed ID: 2113756
    [Abstract] [Full Text] [Related]

  • 31. Paradoxical effect of dopamine medication on cognition in Parkinson's disease: relationship to side of motor onset.
    Hanna-Pladdy B, Pahwa R, Lyons KE.
    J Int Neuropsychol Soc; 2015 Apr 15; 21(4):259-70. PubMed ID: 25923830
    [Abstract] [Full Text] [Related]

  • 32. Cognitive effects of L-deprenyl in Alzheimer's disease.
    Tariot PN, Sunderland T, Weingartner H, Murphy DL, Welkowitz JA, Thompson K, Cohen RM.
    Psychopharmacology (Berl); 1987 Apr 15; 91(4):489-95. PubMed ID: 3108930
    [Abstract] [Full Text] [Related]

  • 33. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP, Boas J.
    Mov Disord; 1997 Mar 15; 12(2):175-82. PubMed ID: 9087975
    [Abstract] [Full Text] [Related]

  • 34. Time course of physical and psychological responses to selegiline monotherapy in newly diagnosed, idiopathic parkinsonism.
    Kirollos C, Charlett A, Bowes SG, Purkiss AG, O'Neill CJ, Weller C, Dickins J, Faulkner G, Nicholson PW, Hunt WB, Dobbs RJ, Dobbs SM.
    Eur J Clin Pharmacol; 1996 Mar 15; 50(1-2):7-18. PubMed ID: 8739805
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Neuropsychological correlates of L-deprenyl therapy in idiopathic parkinsonism.
    Finali G, Piccirilli M, Piccinin GL.
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jan 15; 18(1):115-28. PubMed ID: 8115667
    [Abstract] [Full Text] [Related]

  • 37. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.
    Korczyn AD, Brooks DJ, Brunt ER, Poewe WH, Rascol O, Stocchi F.
    Mov Disord; 1998 Jan 15; 13(1):46-51. PubMed ID: 9452325
    [Abstract] [Full Text] [Related]

  • 38. Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson's disease (MSPD).
    Morrison CE, Borod JC, Brin MF, Hälbig TD, Olanow CW.
    J Neural Transm (Vienna); 2004 Oct 15; 111(10-11):1333-41. PubMed ID: 15480842
    [Abstract] [Full Text] [Related]

  • 39. Cognitive dysfunction in early onset parkinsonism.
    Tsai CH, Lu CS, Hua MS, Lo WL, Lo SK.
    Acta Neurol Scand; 1994 Jan 15; 89(1):9-14. PubMed ID: 8178636
    [Abstract] [Full Text] [Related]

  • 40. Delayed development of symptomatic improvement by (--)-deprenyl in Parkinson's disease.
    Mally J, Kovacs AB, Stone TW.
    J Neurol Sci; 1995 Dec 15; 134(1-2):143-5. PubMed ID: 8747857
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.